<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        AI drug discovery company Reverie Labs has sold its key assets to cell programming and biosecurity company Ginkgo Bioworks for an undisclosed sum.
      </p>
    </li>
    <li>
      <p>
        The acquisition will incorporate Reverie's models, software, and workflows into Ginkgo&rsquo;s system, further expanding its AI/ML capabilities for experimental design and supporting its small molecule programs. Ginkgo will leverage the Reverie Labs assets to boost the company&rsquo;s AI/ML-based discovery services.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.ginkgobioworks.com/2024/02/28/acquiring-reverie-labs-platform-to-enhance-ai-driven-drug-discovery-capabilities-for-customer-programs/">
      Press release
    </a>
  </p>
</div>


Generative AI Infrastructure

<div>
 
 <p>Reverie Labs, an AI drug discovery company, has sold its crucial assets to Ginkgo Bioworks, a cell programming and biosecurity company. The cost of the acquisition has not been disclosed. </p>
 <p>This acquisition will enable Ginkgo Bioworks to incorporate Reverie's systems such as models, software, and workflows into their own system. This will enhance Ginkgo’s capabilities in AI/ML for experimental design and support its small molecule programs. Moreover, Ginkgo will use the Reverie Labs assets to augment its AI/ML-based discovery services. </p>
 
</div>

Reverie Labs sells key AI drug discovery assets to Ginkgo Bioworks for undisclosed sum

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>

 <p>Reverie Labs, a firm specializing in AI drug discovery, has offloaded its primary assets to biosecurity and cell programming enterprise Ginkgo Bioworks in a confidential deal. </p>
 <p>As part of the deal, Ginkgo is set to integrate Reverie's workflows, software, and models into its own system, thus enhancing its AI/ML capabilities in relation to experimental design. This will also assist its programs linked to small molecule. The assets from Reverie Labs will be employed by Ginkgo to enhance its AI/ML-based discovery services. </p>

</div>

All Updates

Reverie Labs sells key AI drug discovery assets to Ginkgo Bioworks for undisclosed sum

Reverie Labs sells key AI drug discovery assets to Ginkgo Bioworks for undisclosed sum